Literature DB >> 22446589

MUC1 carrying core 2 O-glycans functions as a molecular shield against NK cell attack, promoting bladder tumor metastasis.

Yuichiro Suzuki1, Mihoko Sutoh, Shingo Hatakeyama, Kazuyuki Mori, Hayato Yamamoto, Takuya Koie, Hisao Saitoh, Kanemitsu Yamaya, Tomihisa Funyu, Tomonori Habuchi, Yoichi Arai, Minoru Fukuda, Chikara Ohyama, Shigeru Tsuboi.   

Abstract

Core 2 β-1,6-N-acetylglucosaminyltransferase (C2GnT) forms an N-acetylglucosamine branch in O-glycans (core 2 O-glycans) of cell surface glycoproteins. C2GnT-expressing bladder tumors acquire highly metastatic phenotypes by surviving longer in host blood circulation. However, the detailed mechanisms underlying this increased survival remain unclear. In this study, we report that the expression of C2GnT in bladder tumors positively correlates with tumor progression and that bladder tumor cell-surface mucin 1 (MUC1) carrying core 2 O-glycans plays an important role in the evasion from natural killer (NK) cell attack. In C2GnT-expressing bladder tumor cells, heavily core 2 O-glycosylated MUC1 carries poly-N-acetyllactosamine in its O-glycans and galectin-3 binds to MUC1 through this poly-N-acetyllactosamine. The binding of galectin-3 to poly-N-acetyllactosamine in MUC1 core 2 O-glycans attenuates the interaction of the tumor cells with NK cells and interferes with the access of tumor necrosis factor-related apoptosis-inducing ligand to the tumor cell surface. These effects of MUC1 carrying core 2 O-glycans on NK cell attack facilitate C2GnT-expressing tumor cells to evade NK cell immunity and survive longer in host blood circulation. We reveal that MUC1 carrying core 2 O-glycans thus functions as a molecular shield against NK cell attack, thereby promoting bladder tumor metastasis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22446589      PMCID: PMC3396290          DOI: 10.3892/ijo.2012.1411

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  27 in total

Review 1.  Cancer metastasis: building a framework.

Authors:  Gaorav P Gupta; Joan Massagué
Journal:  Cell       Date:  2006-11-17       Impact factor: 41.582

Review 2.  Protein-glycan interactions in the control of innate and adaptive immune responses.

Authors:  Yvette van Kooyk; Gabriel A Rabinovich
Journal:  Nat Immunol       Date:  2008-06       Impact factor: 25.606

Review 3.  Up on the tightrope: natural killer cell activation and inhibition.

Authors:  Lewis L Lanier
Journal:  Nat Immunol       Date:  2008-05       Impact factor: 25.606

Review 4.  Galectins as modulators of tumour progression.

Authors:  Fu-Tong Liu; Gabriel A Rabinovich
Journal:  Nat Rev Cancer       Date:  2005-01       Impact factor: 60.716

Review 5.  TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer.

Authors:  Erika Cretney; Anil Shanker; Hideo Yagita; Mark J Smyth; Thomas J Sayers
Journal:  Immunol Cell Biol       Date:  2006-02       Impact factor: 5.126

6.  Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL.

Authors:  Klaus W Wagner; Elizabeth A Punnoose; Thomas Januario; David A Lawrence; Robert M Pitti; Kate Lancaster; Dori Lee; Melissa von Goetz; Sharon Fong Yee; Klara Totpal; Ling Huw; Viswanatham Katta; Guy Cavet; Sarah G Hymowitz; Lukas Amler; Avi Ashkenazi
Journal:  Nat Med       Date:  2007-09-02       Impact factor: 53.440

Review 7.  The sweet and sour of cancer: glycans as novel therapeutic targets.

Authors:  Mark M Fuster; Jeffrey D Esko
Journal:  Nat Rev Cancer       Date:  2005-07       Impact factor: 60.716

8.  Intracellular retention of the NKG2D ligand MHC class I chain-related gene A in human melanomas confers immune privilege and prevents NK cell-mediated cytotoxicity.

Authors:  Mercedes B Fuertes; María V Girart; Luciana L Molinero; Carolina I Domaica; Lucas E Rossi; María M Barrio; José Mordoh; Gabriel A Rabinovich; Norberto W Zwirner
Journal:  J Immunol       Date:  2008-04-01       Impact factor: 5.422

Review 9.  Galectins: structure, function and therapeutic potential.

Authors:  Ri-Yao Yang; Gabriel A Rabinovich; Fu-Tong Liu
Journal:  Expert Rev Mol Med       Date:  2008-06-13       Impact factor: 5.600

Review 10.  The role of galectin-3 in cancer drug resistance.

Authors:  Tomoharu Fukumori; Hiro-Omi Kanayama; Avraham Raz
Journal:  Drug Resist Updat       Date:  2007-06-04       Impact factor: 18.500

View more
  35 in total

1.  Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis.

Authors:  Gang Liu; Shengjun Lu; Xuanjun Wang; Stephanie T Page; Celestia S Higano; Stephen R Plymate; Norman M Greenberg; Shaoli Sun; Zihai Li; Jennifer D Wu
Journal:  J Clin Invest       Date:  2013-09-09       Impact factor: 14.808

Review 2.  Evolving mechanistic insights into galectin functions.

Authors:  Connie M Arthur; Marcelo Dias Baruffi; Richard D Cummings; Sean R Stowell
Journal:  Methods Mol Biol       Date:  2015

3.  Tumor-released Galectin-3, a soluble inhibitory ligand of human NKp30, plays an important role in tumor escape from NK cell attack.

Authors:  Wei Wang; Huaijian Guo; Jianlin Geng; Xiaodong Zheng; Haiming Wei; Rui Sun; Zhigang Tian
Journal:  J Biol Chem       Date:  2014-10-14       Impact factor: 5.157

4.  Stage Dependence, Cell-Origin Independence, and Prognostic Capacity of Serum Glycan Fucosylation, β1-4 Branching, β1-6 Branching, and α2-6 Sialylation in Cancer.

Authors:  Shadi Ferdosi; Douglas S Rehder; Paul Maranian; Erik P Castle; Thai H Ho; Harvey I Pass; Daniel W Cramer; Karen S Anderson; Lei Fu; David E C Cole; Tao Le; Xifeng Wu; Chad R Borges
Journal:  J Proteome Res       Date:  2017-11-21       Impact factor: 4.466

5.  Single molecule study of heterotypic interactions between mucins possessing the Tn cancer antigen.

Authors:  Kristin E Haugstad; Bjørn T Stokke; C Fred Brewer; Thomas A Gerken; Marit Sletmoen
Journal:  Glycobiology       Date:  2014-12-19       Impact factor: 4.313

Review 6.  Mucins in pancreatic cancer and its microenvironment.

Authors:  Sukhwinder Kaur; Sushil Kumar; Navneet Momi; Aaron R Sasson; Surinder K Batra
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-07-16       Impact factor: 46.802

7.  Unlocking Cancer Glycomes from Histopathological Formalin-fixed and Paraffin-embedded (FFPE) Tissue Microdissections.

Authors:  Hannes Hinneburg; Petra Korać; Falko Schirmeister; Slavko Gasparov; Peter H Seeberger; Vlatka Zoldoš; Daniel Kolarich
Journal:  Mol Cell Proteomics       Date:  2017-01-25       Impact factor: 5.911

8.  Mucin-1 Increases Renal TRPV5 Activity In Vitro, and Urinary Level Associates with Calcium Nephrolithiasis in Patients.

Authors:  Mingzhu Nie; Manjot S Bal; Zhufeng Yang; Jie Liu; Carolina Rivera; Andrea Wenzel; Bodo B Beck; Khashayar Sakhaee; Denise K Marciano; Matthias T F Wolf
Journal:  J Am Soc Nephrol       Date:  2016-04-01       Impact factor: 10.121

9.  Interactions of mucins with the Tn or Sialyl Tn cancer antigens including MUC1 are due to GalNAc-GalNAc interactions.

Authors:  Kristin E Haugstad; Soosan Hadjialirezaei; Bjørn T Stokke; C Fred Brewer; Thomas A Gerken; Joy Burchell; Gianfranco Picco; Marit Sletmoen
Journal:  Glycobiology       Date:  2016-06-09       Impact factor: 4.313

10.  Acceptor specificities and selective inhibition of recombinant human Gal- and GlcNAc-transferases that synthesize core structures 1, 2, 3 and 4 of O-glycans.

Authors:  Yin Gao; Rajindra P Aryal; Tongzhong Ju; Richard D Cummings; Gagandeep Gahlay; Donald L Jarvis; Khushi L Matta; Jason Z Vlahakis; Walter A Szarek; Inka Brockhausen
Journal:  Biochim Biophys Acta       Date:  2013-04-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.